Table 2 Incidence of adverse events in Groups A to H
Number of subjects with adverse events considered possible related to study drug | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Group and dose of SMT19969 | ||||||||||
Adverse event | A-H | A | B | C | D | E | F | G | H | |
Placebo | 2 mg | 20 mg | 100 mg | 400 mg | 1,000 mg | 2,000 mg | 200 mg BID | 500 mg BID | ||
(N = 14) | (N = 3) | (N = 3) | (N = 6) | (N = 6) | TP1(N = 6) | TP2(N = 6) | (N = 6) | (N = 6) | (N = 6) | |
Diarrhoea | 3 | 1 | 2 | 1 | 2 | |||||
Abdominal distension | 1 | 1 | 1 | |||||||
Abdominal pain | 1 | 1 | 1 | |||||||
Duodeno-gastric reflux | 1 | |||||||||
Flatulence | 1 | 1 | ||||||||
Dyspepsia | 1 | |||||||||
Feeling hot | 1 | |||||||||
Paraesthesia | 1 | |||||||||